Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS’ Andreotti Talks BD Beyond 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncology, virology and cardiovascular remain top therapeutic priorities in mid-term, but longer term focus at BMS is shifting to oncology, CNS and cardiovascular and metabolic diseases, CEO Lamberto Andreotti tells analysts at Sanford F. Bernstein conference.


Related Content

Plavix Takes A Final Bow, But Will It Go Gracefully?
Sign Of The Times: Late-Stage Cancer Vaccines On Display At ASCO
Eliquis Delay Fuels Speculation About Advisory Committee Meeting
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
BMS' Purchase Of Amira: When An Acquisition Is Really An Asset Sale


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts